Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study

被引：37

作者：

Martinez-Cuadron, David ^{[1
,2
]}

Megias-Vericat, Juan E. ^{[3
]}

Serrano, Josefina ^{[4
]}

Martinez-Sanchez, Pilar ^{[5
]}

Rodriguez-Arboli, Eduardo ^{[6
]}

Gil, Cristina ^{[7
]}

Aguiar, Eliana ^{[8
]}

Bergua, Juan ^{[9
]}

Lopez-Lorenzo, Jose L. ^{[10
]}

Bernal, Teresa ^{[11
]}

Espadana, Ana ^{[12
]}

Colorado, Mercedes ^{[13
]}

Rodriguez-Medina, Carlos ^{[14
]}

Lopez-Pavia, Maria ^{[15
]}

Tormo, Mar ^{[16
]}

Algarra, Lorenzo ^{[17
]}

Amigo, Maria-Luz ^{[18
]}

Sayas, Maria J. ^{[19
]}

Labrador, Jorge ^{[20
]}

Rodriguez-Gutierrez, Juan, I ^{[21
]}

Benavente, Celina ^{[22
]}

Costilla-Barriga, Lissette ^{[23
]}

Garcia-Boyero, Raimundo ^{[24
]}

Lavilla-Rubira, Esperanza ^{[25
]}

Vives, Susana ^{[26
]}

Herrera, Pilar ^{[27
]}

Garcia-Belmonte, Daniel ^{[28
]}

Herraez, Maria Mar ^{[29
]}

Esteves, Graca Vasconcelos ^{[30
]}

Gomez-Roncero, Maria, I ^{[31
]}

Cabello, Ana ^{[32
]}

Bautista, Guiomar ^{[33
]}

Balerdi, Amaia ^{[34
]}

Mariz, Jose ^{[35
]}

Boluda, Blanca ^{[1
,2
]}

Sanz, Miguel A. ^{[2
]}

Montesinos, Pau ^{[1
,2
]}

机构：

[1] Hosp Univ & Politecn La Fe, Valencia, Spain

[2] Inst Invest Sanitaria La Fe IISLAFE, Valencia, Spain

[3] Hosp Univ & Politecn La Fe, Serv Farm, Area Med, Valencia, Spain

[4] Hosp Univ Reina Sofia IMIBIC, Cordoba, Spain

[5] Hosp Univ 12 Octubre, Madrid, Spain

[6] Hosp Univ Virgen Rocio, Seville, Spain

[7] Hosp Gen Univ Alicante, Alicante, Spain

[8] Ctr Hosp Sao Joao, Porto, Portugal

[9] Hosp San Pedro Alcantara, Caceres, Spain

[10] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain

[11] Hosp Univ Cent Asturias, Asturias, Spain

[12] Ctr Hosp & Univ Coimbra, EPE, Coimbra, Portugal

[13] Hosp Univ Marques Valdecilla, Santander, Spain

[14] Hosp Univ Gran Canaria Doctor Negrin, Las Palmas Gran Canaria, Spain

[15] Hosp Gen Univ Valencia, Valencia, Spain

[16] Hosp Clin Univ, INCLIVA Biomed Res Inst, Valencia, Spain

[17] Hosp Gen Univ Albacete, Albacete, Spain

[18] Hosp Gen Univ Morales Meseguer, Murcia, Spain

[19] Hosp Univ Doctor Peset, Valencia, Spain

[20] Hosp Univ Burgos, Burgos, Spain

[21] Basurtuko Unibertsitate Ospitalea, Bizkaia, Spain

[22] Hosp Clin San Carlos, Madrid, Spain

[23] Hosp Univ Miguel Servet, Zaragoza, Spain

[24] Hosp Gen Univ Castello, Castellon de La Plana, Spain

[25] Hosp Lucus Augusti, Lugo, Spain

[26] Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Jose Carreras Leukemia Res Inst, Barcelona, Spain

[27] Hosp Univeristario Ramon Y Cajal, Madrid, Spain

[28] Hosp Sanitas Zarzuela, Madrid, Spain

[29] Hosp Santa Barbara Puertollano, Ciudad Real, Spain

[30] Hosp Santa Maria, Lisbon, Portugal

[31] Hosp Virgen Salud, Toledo, Spain

[32] Hosp Univ Nuestra Senora Candelaria, Tenerife, Spain

[33] Hosp Univ Puerta Hierro, Madrid, Spain

[34] Hosp Univ Cruces, Bizkaia, Spain

[35] Inst Portugues Oncol Porto, Porto, Portugal

来源：

BLOOD ADVANCES | 2022年 / 6卷 / 04期

关键词：

ACUTE MYELOGENOUS LEUKEMIA; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PROGNOSTIC-FACTOR; EARLY DEATH; AML; THERAPY; CYTOGENETICS; OLDER; AGE;

D O I：

10.1182/bloodadvances.2021005335

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Secondary acute myeloid leukemia (sAML) comprises a heterogeneous group of patients and is associated with poor overall survival (OS). We analyze the characteristics, treatment patterns, and outcomes of adult patients with sAML in the Programa Espanol de Tratamientos en Hematologia (PETHEMA) registry. Overall, 6211 (72.9%) were de novo and 2310 (27.1%) had sAML, divided into myelodysplastic syndrome AML (MDS-AML, 44%), MDS/myeloproliferative AML (MDS/MPN-AML, 10%), MPN-AML (11%), therapy-related AML (t-AML, 25%), and antecedent neoplasia without prior chemotherapy/radiotherapy (neo-AML, 9%). Compared with de novo, patients with sAML were older (median age, 69 years), had more Eastern Cooperative Oncology Group >= 2 (35%) or high-risk cytogenetics (40%), less FMS-like tyrosine kinase 3 internal tandem duplication (11%), and nucleophosmin 1 (NPM1) mutations (21%) and received less intensive chemotherapy regimens (38%) (all P < .001). Median OS was higher for de novo than sAML (10.9 vs 5.6 months; P < .001) and shorter in sAML after hematologic disorder (MDS, MDS/MPN, or MPN) compared with t-AML and neo-AML (5.3 vs 6.1 vs 5.7 months, respectively; P = .04). After intensive chemotherapy, median OS was better among patients with de novo and neo-AML (17.2 and 14.6 months, respectively). No OS differences were observed after hypomethylating agents according to type of AML. sAML was an independent adverse prognostic factor for OS. We confirmed high prevalence and adverse features of sAML and established its independent adverse prognostic value.

引用

页码：1278 / 1295

页数：18

共 53 条

[1] Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents
Andersen, MK
Christiansen, DH
Kirchhoff, M
Pedersen-Bjergaard, J
[J]. GENES CHROMOSOMES & CANCER, 2001, 31 (01) : 33 - 41
[2] Age and acute myeloid leukemia
Appelbaum, FR
Gundacker, H
Head, DR
Slovak, ML
Willman, CL
Godwin, JE
Anderson, JE
Petersdorf, SH
[J]. BLOOD, 2006, 107 (09) : 3481 - 3485
[3] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Arber, Daniel A.
Orazi, Attilio
Hasserjian, Robert
Thiele, Jurgen
Borowitz, Michael J.
Le Beau, Michelle M.
Bloomfield, Clara D.
Cazzola, Mario
Vardiman, James W.
[J]. BLOOD, 2016, 127 (20) : 2391 - 2405
[4] Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden
Åström, M
Bodin, L
Nilsson, I
Tidefelt, U
[J]. BRITISH JOURNAL OF CANCER, 2000, 82 (08) : 1387 - 1392
[5] Improved outcome for AML patients over the years 2000-2014
Bertoli, Sarah
Tavitian, Suzanne
Huynh, Anne
Borel, Cecile
Guenounou, Sarah
Luquet, Isabelle
Delabesse, Eric
Sarry, Audrey
Laurent, Guy
Attal, Michel
Huguet, Francoise
Berard, Emilie
Recher, Christian
[J]. BLOOD CANCER JOURNAL, 2017, 7
[6] Therapy-related acute myelogenous leukemia and myelodysplastic syndrome
Borthakur G.
Estey E.E.
[J]. Current Oncology Reports, 2007, 9 (5) : 373 - 377
[7] Survival Is Poorer in Patients With Secondary Core-binding Factor Acute Myelogenous Leukemia Compared With De Novo Core-binding Factor Leukemia
Borthakur, Gautam
Lin, E.
Jain, Nitin
Estey, Elihu E.
Cortes, Jorge E.
O'Brien, Susan
Faderl, Stefan
Ravandi, Farhad
Pierce, Sherry
Kantarjian, Hagop
[J]. CANCER, 2009, 115 (14) : 3217 - 3221
[8] Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
Campbell, Peter J.
Baxter, E. Joanna
Beer, Philip A.
Scott, Linda M.
Bench, Anthony J.
Huntly, Brian J. P.
Erber, Wendy N.
Kusec, Rajko
Larsen, Thomas Stauffer
Giraudier, Stephane
Le Bousse-Kerdiles, Marie-Caroline
Griesshammer, Martin
Reilly, John T.
Cheung, Betty Y.
Harrison, Claire N.
Green, Anthony R.
[J]. BLOOD, 2006, 108 (10) : 3548 - 3555
[9] CERVANTES F, 1991, ACTA HAEMATOL-BASEL, V85, P124
[10] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
Cheson, BD
Bennett, JM
Kopecky, KJ
Büchner, T
Willman, CL
Estey, EH
Schiffer, CA
Döhner, H
Tallman, MS
Lister, TA
LoCocco, F
Willemze, R
Biondi, A
Hiddemann, W
Larson, RA
Löwenberg, B
Sanz, MA
Head, DR
Ohno, R
Bloomfield, CD
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4642 - 4649

← 1 2 3 4 5 6 →